other material
confidence high
sentiment positive
materiality 0.75
Tonix secures GPO coverage for TONMYA, expanding commercial access to ~35M patients
Tonix Pharmaceuticals Holding Corp.
- Agreement effective May 1, 2026 with leading GPO provides coverage for ~35M U.S. commercial lives (20% of ~177M total).
- TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years; commercially launched November 2025.
- TONMYA now covered under Medicaid in 38 states, representing ~55M beneficiaries (73% of ~75M Medicaid lives).
- Coverage includes standard utilization management criteria; patient savings program available for eligible commercially insured.
- CEO Seth Lederman emphasizes continued pursuit of additional commercial and government channel coverage.